The Global Market for Marine Biotechnology is Projected to Reach US$4.8 Billion by 2020
Rising Focus on Environmental
Sustainability Drives Growth in the Global Marine Biotechnology Market,
According to a New Report by Global
Industry Analysts, Inc.
GIA announces the release of a comprehensive global
report on Marine Biotechnology. The
global market for Marine Biotechnology is projected to reach US$4.8 billion by
2020, driven by the rising global focus on environmental sustainability
and the ensuing increase in investments in marine biotechnology research.
Marine biotechnology is a discipline with huge
potential, given the vast biodiversity of life in the oceans. Development of marine-derived
extracts and compounds has the capability to significantly impact the field of cosmetics,
pharmaceuticals, fine chemicals, nutritional supplements, and agrichemicals, among
others. By
studying marine organisms and resources, marine biotechnology seeks to provide
potential solutions to address challenges related to food security, healthcare,
industrial activities, environmental sustainability and preservation of marine
resources. Marine ingredients are increasingly being used in food,
agriculture and cosmetic industries. In the coming years, growth will be driven
by the growing need for environmentally safe, bio-derived feedstock across a
wide range of industries. Effervescent technology developments and the resulting
availability of a diverse range of marine derived products will also help spur
growth in the market. With environmental pollution throwing the spotlight on
sustainable industrial development, there exists huge demand for suitable,
scalable, economically, socially and environmentally sustainable feedstock
options for the manufacturing industry.
One of the most successful applications of marine
biotechnology on a commercial scale is the development of Marine derived drugs.
In drug discovery, marine microbes are being researched as potential sources of
drugs for the treatment of drug-resistant bacterial infections. Marine
biomedicine is expected to play an important role in improving healthcare by
assisting researchers in exploring new compounds and materials with potent uses
in preventive therapeutics, personal care, nutraceuticals and health products.
In the industrial sector, the technology flaunts the potential to help
scientists develop and engineer non-toxic, affordable antifouling technologies,
anti-corrosive coatings, and self-cleaning surfaces.
As stated by the new market research report on Marine
Biotechnology, the United States represents the largest market worldwide.
R&D projects in the country are focused on the production of algae-derived
bioenergy. Europe is forecast to emerge as a major regional market, given the
continent’s yet unexplored and underexploited marine resources. Of special
importance is the application of marine biotechnology in the medical sector
with the region’s pharmaceutical industry having already developed commercially
viable marine derived drugs to treat a range of diseases including cancer. Asia-Pacific
is forecast to grow at a compounded annual rate of 5.4% over the analysis
period.
Major players covered in the report include Aker
BioMarine AS, Aqua Bio Technology ASA, BASF SE, CP Kelco, Cyanotech Corp., FMC
Health and Nutrition, GlycoMar Ltd., Jazz Pharmaceuticals plc, Lonza Group Ltd,
Marinova Pty Ltd, New England Biolabs Inc, oceanBASIS GmbH, PharmaMar S.A, PML
Applications Ltd., Prolume Ltd, Royal DSM N.V, Sea Run Holdings Inc., SEPPIC,
and Tequesta BioVentures, among others.
Comments
Post a Comment